Evolus, Inc. Common StockNASDAQ: EOLS

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

· Issued by Evolus, Inc. Common Stock via Business Wire

Summary by 6ix AI

Evolus, Inc., a beauty company that sells aesthetic injectables, granted an aggregate of 194,335 restricted stock units (rights to receive company shares later) of its common stock to 25 newly hired non-executive employees during August 2026 to November 2026.

Key details

  • The units vest 25% on each anniversary of the vesting commencement date, subject to each employee's continued service and the terms of the 2023 Inducement Incentive Plan and the applicable RSU agreement.
  • The compensation committee of the board of directors approved the awards under Evolus' 2023 Inducement Incentive Plan as inducements material to the new employees joining Evolus, under Nasdaq Listing Rule 5635(c)(4), a stock exchange rule that allows such grants to new hires without a shareholder vote on the plan.

What’s still pending

  • Vesting of each award depends on the employee's continued service.

6ix AI wrote this summary from the release below and checked it against the release.

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during August 2026 to November 2026 of an aggregate of 194,335 restricted stock units (RSUs) of the company’s common stock to 25 newly hired non-executive employees.

The RSUs vest 25% on each anniversary of the vesting commencement date, subject to each employee’s continued service and the terms of the 2023 Inducement Incentive Plan and the applicable RSU agreement. The awards were approved by the compensation committee of the company’s board of directors under Evolus’ 2023 Inducement Incentive Plan as inducements material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo®, the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau®, Nuceiva®, and Evolysse® are registered trademarks of Evolus, Inc.
Profhilo® is a registered trademark of IBSA Institut Biochimique SA.

View original source (Business Wire)Evolus, Inc. Common Stock on 6ix

Story so far

Earlier from Evolus, Inc. Common Stock

All Evolus, Inc. Common Stock news releases